Mostra el registre parcial de l'element
Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection
dc.contributor.author | Pradenas, Edwards | |
dc.contributor.author | Trinité, Benjamin | |
dc.contributor.author | Urrea, Víctor | |
dc.contributor.author | Marfil, Silvia | |
dc.contributor.author | Tarrés-Freixas, Ferran | |
dc.contributor.author | Ortiz, Raquel | |
dc.contributor.author | Rovirosa, Carla | |
dc.contributor.author | Rodon, Jordi | |
dc.contributor.author | Vergara-Alert, Júlia | |
dc.contributor.author | Segalés, Joaquim | |
dc.contributor.author | Guallar, Victor | |
dc.contributor.author | Valencia, Alfonso | |
dc.contributor.author | Izquierdo-Useros, Nuria | |
dc.contributor.author | Noguera-Julian, Marc | |
dc.contributor.author | Carrillo, Jorge | |
dc.contributor.author | Paredes, Roger | |
dc.contributor.author | Mateu, Lourdes | |
dc.contributor.author | Chamorro, Anna | |
dc.contributor.author | Toledo, Ruth | |
dc.contributor.author | Massanella, Marta | |
dc.contributor.author | Clotet, Bonaventura | |
dc.contributor.author | Blanco, Julià | |
dc.contributor.other | Producció Animal | ca |
dc.date.accessioned | 2022-03-09T11:26:17Z | |
dc.date.available | 2022-03-09T11:26:17Z | |
dc.date.issued | 2022-01-24 | |
dc.identifier.citation | Pradenas, Edwards, Benjamin Trinité, Víctor Urrea, Silvia Marfil, Ferran Tarrés-Freixas, Raquel Ortiz, Carla Rovirosa, Jordi Rodon, Júlia Vergara-Alert and Joaquim Segalés et al. 2022. "Clinical Course Impacts Early Kinetics,Magnitude, And Amplitude Of SARS-Cov-2 Neutralizing Antibodies Beyond 1 Year After Infection". Cell Reports Medicine 3 (2): 100523. doi:10.1016/j.xcrm.2022.100523. | ca |
dc.identifier.issn | 2666-3791 | ca |
dc.identifier.uri | http://hdl.handle.net/20.500.12327/1649 | |
dc.description.abstract | To understand the determinants of long-term immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the concurrent impact of vaccination and emerging variants, we follow a prospective cohort of 332 patients with coronavirus disease 2019 (COVID-19) over more than a year after symptom onset. We evaluate plasma-neutralizing activity using HIV-based pseudoviruses expressing the spike of different SARS-CoV-2 variants and analyze them longitudinally using mixed-effects models. Long-term neutralizing activity is stable beyond 1 year after infection in mild/asymptomatic and hospitalized participants. However, longitudinal models suggest that hospitalized individuals generate both short- and long-lived memory B cells, while the responses of non-hospitalized individuals are dominated by long-lived B cells. In both groups, vaccination boosts responses to natural infection. Long-term (>300 days from infection) responses in unvaccinated participants show a reduced efficacy against beta, but not alpha nor delta, variants. Multivariate analysis identifies the severity of primary infection as an independent determinant of higher magnitude and lower relative cross-neutralization activity of long-term neutralizing responses. | ca |
dc.format.extent | 13 | ca |
dc.language.iso | eng | ca |
dc.publisher | Cell Press | ca |
dc.relation.ispartof | Cell Reports Medicine | ca |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | ca |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.title | Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection | ca |
dc.type | info:eu-repo/semantics/article | ca |
dc.description.version | info:eu-repo/semantics/publishedVersion | ca |
dc.rights.accessLevel | info:eu-repo/semantics/openAccess | |
dc.embargo.terms | cap | ca |
dc.subject.udc | 619 | ca |
dc.identifier.doi | https://doi.org/10.1016/j.xcrm.2022.100523 | ca |
dc.contributor.group | Sanitat Animal | ca |
Fitxers en aquest element
Aquest element apareix en la col·lecció o col·leccions següent(s)
-
ARTICLES CIENTÍFICS [2.838]